Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer

OBJECTIVE(S): In the treatment of castration-resistant prostate cancer (CRPC) with bone metastases, radium-223 dichloride (Ra-223) is the only bone-targeted drug that shows survival benefits. Completing six courses of Ra-223 treatment is thought to be associated with better patient survival, but thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Kazuya, Kawasaki, Yoshihide, Sakayauchi, Toru, Takahashi, Chiaki, Katagiri, Yu, Tanabe, Takaya, Ishikawa, Yojiro, Fujimoto, Keisuke, Kubozono, Masaki, Kozumi, Maiko, Abe, Keiko, Narazaki, Kakutaro, Tasaka, Shun, Umezawa, Rei, Yamamoto, Takaya, Takahashi, Noriyoshi, Suzuki, Yu, Kishida, Keita, Omata, So, Ito, Akihiro, Jingu, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803628/
https://www.ncbi.nlm.nih.gov/pubmed/36619192
http://dx.doi.org/10.22038/AOJNMB.2022.67136.1468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803628/
https://www.ncbi.nlm.nih.gov/pubmed/36619192
http://dx.doi.org/10.22038/AOJNMB.2022.67136.1468

Ejemplares similares